---
created: 2025-04-13
updated: 2025-04-13T10:53
id: JQtI!Hx_]%
specialty: pharmaco
specialty_id: 487
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::06-other-cancer-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::*basics
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab::*basics
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab"
type: flashcard
---

# Question
Monoclonal antibodies can sometimes cause a(n) **infusion reaction** immediately upon IV administration

---

# Answer
